Drug Profile
Anti-PSCA-A11-antibody-I-124 - ImaginAb
Alternative Names: 124-I-anti-PSCA-A11-minibody - ImaginAb; 124I-A11-PSCA-minibody - ImaginAb; Anti-prostate-stem-cell-antigen-A11-antibody-I-124 - ImaginAb; Anti-PSCA-A11-minibody-I-124 - ImaginAbLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator University of California at Los Angeles
- Developer ImaginAb Inc; University of California at Los Angeles
- Class Antibody diagnostics; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder cancer; Pancreatic cancer; Prostate cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Bladder-cancer(Diagnosis) in USA (IV, Injection)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Pancreatic-cancer(Diagnosis) in USA (IV, Injection)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Prostate-cancer(Diagnosis) in USA (IV, Injection)